Rationale: Carbapenems are recommended for treatment of drug-resistant tuberculosis.
Optimal dosing remains uncertain. Objectives: To evaluate the 14-day bactericidal activity of …

Improving treatment outcomes in multidrug‐resistant tuberculosis (MDR‐TB) is partly
hampered by inadequate effective antitubercular agents. Development of bedaquiline and …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

Background Bedaquiline improves treatment outcomes in patients with rifampin-resistant
(RR) tuberculosis but prolongs the QT interval and carries a black-box warning from the US …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

Corbett expects that bedaquiline will soon find its way into TB regimens for HIV-positive
patients with MDR-TB. The simultaneous treatment of HIV and TB, however, raises the …

BACKGROUND: The World Health Organization recommends adding bedaquiline or
delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective …

The clinical development and regulatory approval of bedaquiline, delamanid and
pretomanid over the last decade brought about significant progress in the management of …

Background Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was
associated with an increased risk of death in a phase 2b clinical trial, resulting in caution …

The current treatment for drug-resistant tuberculosis (TB) is long, complex, and associated
with severe and life-threatening side effects and poor outcomes. For the first time in nearly …